TESS yields 88.77% · JNJ yields 2.13%● Live data
📍 TESS pulled ahead of the other in Year 1
Combined, TESS + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TESS + JNJ for your $10,000?
TESSCO Technologies Incorporated manufactures and distributes technology products and solutions for wireless infrastructure market in the United States and internationally. It operates through two segments, Carrier and Commercial. The company offers base station infrastructure products, including base station antennas, cable and transmission lines, small towers, lightning protection devices, connectors, power systems, enclosures, grounding products, jumpers, miscellaneous hardware products, and mobile antennas to build, repair, and upgrade wireless broadband systems. It also provides network systems products, such as fixed and mobile broadband radio equipment, wireless networking filtering and distributed antenna systems, two-way radios, and security and surveillance products. In addition, the company offers installation, test, and maintenance products comprising analysis equipment; and various frequency, voltage, and power-measuring devices, as well as tools, hardware, GPS and safety products, and replacement and component parts and supplies to install, tune, and maintain wireless communications equipment. The company sells its products to carrier and public network operators, tower owners, program managers, contractors and integrators, private system operators, federal governments, state and local governments, manufacturers, national solutions providers, and value-added resellers under the Ventev brand. TESSCO Technologies Incorporated was founded in 1982 and is headquartered in Hunt Valley, Maryland.
Full TESS Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.